Does Semaglutide Protect Against Limb Complications Like Amputation? A Large Meta-Analysis | Research

The takeaway

A meta-analysis of 19 trials with over 51,000 participants examined whether semaglutide reduces peripheral artery disease complications like limb events in people with diabetes or obesity.

51,557 participants
Largest meta-analysis to date examining semaglutide's impact on limb events

What the researchers found

The pooled analysis of 19 RCTs with 51,557 participants assessed semaglutide's impact on peripheral limb events, providing the most comprehensive evidence to date on this important but understudied outcome.

Why it matters

PAD affects millions of people with diabetes and can lead to amputation. If semaglutide protects limbs in addition to the heart, it could prevent devastating complications that dramatically reduce quality of life.

How the study worked

Systematic review and meta-analysis of 19 randomized controlled trials following PRISMA guidelines, pooling data from 51,557 participants.

What this study cannot tell us

Limb events were typically secondary endpoints in the included trials; heterogeneity in how limb events were defined and reported across studies; follow-up durations may have been insufficient to capture all limb outcomes.

How to read the evidence

Meta-analysis of randomized controlled trials — high-quality evidence synthesis, though limb events were secondary endpoints in most included studies.

When this study was published

Published in 2026, providing the most current pooled evidence on semaglutide and peripheral vascular outcomes.

The bigger picture

This extends the known benefits of GLP-1 drugs beyond weight loss and cardiovascular protection to peripheral vascular health, potentially positioning semaglutide as a comprehensive vascular protectant.

Questions still open

Should patients with PAD and diabetes be prioritized for semaglutide therapy?
Is the limb-protective effect mediated by weight loss, improved glycemic control, or direct vascular effects?

Common questions

What are limb events in diabetes?

Limb events include peripheral artery disease complications like reduced blood flow, chronic wounds, infections, and in severe cases, amputation — primarily affecting the legs and feet of people with diabetes.

Could semaglutide prevent amputations in diabetic patients?

This meta-analysis investigated that question by pooling data from over 51,000 participants. The results help clarify whether semaglutide's known cardiovascular benefits extend to protecting limbs as well.

Read the original research

Impact of Semaglutide on Limb Events: A Meta-Analysis of Randomized Controlled Trials.

European journal of preventive cardiology

View on PubMed ↗Publisher’s paper ↗

Citation

Cesaro, Arturo; Acerbo, Vincenzo; Longo, Miriam; Antonucci, Alessandra; Maiorino, Maria Ida; Monaco, Maria Grazia; Martelli, Eugenio; Giudice, Giorgio; Esposito, Katherine; Giorgino, Francesco; Federici, Massimo; Calabrò, Paolo. (2026). Impact of Semaglutide on Limb Events: A Meta-Analysis of Randomized Controlled Trials.. European journal of preventive cardiology. https://doi.org/10.1093/eurjpc/zwag077